Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393738 · ClinicalTrials.gov registry record · Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
A Phase 1 study of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), sponsored by Arvinas.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 255
- Enrollment target
- 17
- Study locations
NCT06393738 is a Phase 1 study of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) that is actively recruiting participants, run by Arvinas. The registered enrollment target is 255 participants. The trial reports 17 study locations across 12 states.
The verdict
NCT06393738, a Phase 1 study of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), is actively recruiting participants, sponsored by Arvinas.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 255 participants
- Enrollment target
- 17
- Study locations
Study Summary
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Conditions Studied
Interventions
- DRUG Glofitamab
- DRUG ARV-393
Study Locations (17)
Other
- Clinical Trial Site - Copenhagen
- Clinical Trial Site - Odense C
- Clinical Trial Site - Barcelona
- Clinical Trial Site - Madrid
- Clinical Trial Site - Salamanca
New York
- Clinical Trial Site - New York
- Clinical Trial Site - New York
Connecticut
- Clinical Trial Site - New Haven
Michigan
- Clinical Trial Site - Detroit
New Jersey
- Clinical Trial Site - New Brunswick
Ohio
- Clinical Trial Site - Cleveland
Tennessee
- Clinical Trial Site - Nashville
Texas
- Clinical Trial Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2024-09-05 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06393738
The ClinicalTrials.gov registry entry for NCT06393738 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arvinas, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) appearing as the primary indexed condition, and to 2 interventions - of which Glofitamab is the first listed.
NCT06393738 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06393738 about?
NCT06393738 is a clinical study titled "A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.". This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by b...
What is the current status of trial NCT06393738?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 255 participants. The study started on 2024-09-05. Estimated completion is 2028-03.
What conditions does trial NCT06393738 study?
This clinical trial studies the following conditions: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL).
What interventions are being tested in trial NCT06393738?
The interventions under investigation include: Glofitamab (DRUG), ARV-393 (DRUG).
Who is sponsoring clinical trial NCT06393738?
This trial is sponsored by Arvinas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393738 being conducted?
This trial has 17 study locations across Connecticut, Michigan, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
All registered trials for this condition
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.